Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
This is federal law, not Novo Nordisk's policy
They support fat reduction, healthier testosterone levels, improved fertility potential, and better sexual function
The MHRA approved the indication in July 2024 based on the SELECT trial, in which Wegovy 2.4 mg reduced heart attack, stroke, and cardiovascular death by 20% over an average of 33 months in adults with overweight or obesity and existing cardiovascular disease
Long term use may lead to serious complications such as stomach bleeding and kidney problems
US$ 25.96
US$ 26.66
US$ 29.43
US$ 25.69
US$ 28.48
US$ 21.02
US$ 21.45
US$ 23.13
